50 mg 89Zr-DFO-Nimotuzumab clinical trials

Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

This study looks for a better way to find specific cancer cells (EGFR-positive) in lung and bowel cancers. We use a special scan (PET) after giving a small amount of a test medicine to see if it lights up these cancer cells, helping doctors choose the best treatments.